Bone morphogenetic protein receptor 2 in patients with idiopathic portal hypertension

Andrea De Gottardi a, b, #, Susana Seijo a, #, Montserrat Miliá c, d, M. Isabel Alvarez d, Miquel Bruguera a, Juan G. Abraldes a, e, Jaime Bosch a, e, Juan-Carlos García-Pagán a, e, *

a Hepatic Hemodynamic Laboratory, Liver Unit, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
b Hepatology, Department of Clinical Research, University of Berne, Switzerland
c Biochemical and Molecular Genetics Department, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
d CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Spain
e Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Spain

Received: August 23, 2011; Accepted: November 22, 2011

Abstract

In idiopathic portal hypertension (IPH) typical vascular lesions are present in the branches of the portal vein or in the perisinusoidal area of the liver. Similar histological alterations have been reported in the pulmonary vasculature of patients with idiopathic pulmonary artery hypertension (IPAH). As IPAH is associated with mutations of the bone morphogenetic protein receptor 2 (BMPR2) gene, the aim of this study was to investigate whether this association might also be found in patients with IPH. Twenty-three samples belonging to 21 unrelated caucasian patients with IPH followed in the hepatic haemodynamic laboratory of the Hospital Clinic in Barcelona were included in the study. All patients were studied for the entire open reading frame and splice site of the BMPR2 gene by direct sequencing and multiple ligation probe amplification (MLPA) in order to detect large deletions/duplications. None of the 23 patients had pulmonary artery hypertension. Four patients presented one single nucleotide polymorphism (SNP) in intron 5, four patients had a SNP in exon 12 and a SNP in exon 1 was found in two cases. Two patients had both intron 5 and exon 12 polymorphisms. All SNPs were previously described. Except for these three SNPs, neither mutations nor rearrangements have been identified in the BMPR2 gene in this population. We did not detect mutations or rearrangements in the coding region of the BMPR2 gene in our patients with IPH. These findings suggest that, in contrast to IPAH, mutations in BMPR2 are not involved in the pathogenesis of IPH.

Keywords: hepatopetal sclerosis • non-cirrhotic portal hypertension • bone morphogenetic proteins • pulmonary artery hypertension • HIV • BMPR2 gene

Introduction

Idiopathic portal hypertension is a progressively debilitating and life-threatening disease of unknown etiology characterized by the absence of cirrhosis or portal vein obstruction [1].

Typical lesions are generally vascular and are present in the portal vein, its branches or in the perisinusoidal area of the liver.

Essentially, there is a marked sub-endothelial thickening of the large and medium-sized branches of the portal vein, with obliteration of small portal venules, microthrombi incorporated into the vessel wall and preisinusoidal fibrosis [2, 3].

The mechanisms causing these lesions remain largely unknown. Prothrombotic disorders are considered important causal features [4, 5], but also infections [6], trace metals and chemicals [7] and immunological factors [8, 9] have been proposed. Furthermore, genetic mutations may play a role in the pathogenesis of IPH [10, 11]. Familial aggregation has been described, raising the question about the existence of one or more genes at the origin of this disorder [11].

Interestingly, the pathological alterations observed in the smallest vessels of the lung of patients with IPAH, i.e. intimal
proliferation with perivascular fibrosis and muscular hypertrophy of the media [12] are very similar to those found in the liver in IPH [5]. In addition, some patients with IPH also present clinical features of IPAH [13].

Bone morphogenetic protein receptor 2 (BMPR2) gene, which encodes a membrane receptor of the transforming growth factor beta (TGF-β) superfamily, has been mapped on chromosome 2q33 (locus PPH1) and the sequence of this 4-kb gene is composed by 13 exons and encodes a 1038-amino acid protein [14]. Mutations in BMPR2 account for 7–25% of the IPAH forms and for up to 80% of the familial forms of pulmonary arterial hypertension [15–17]. Large rearrangements account for 12% in familial forms of pulmonary arterial hypertension and 5% in sporadic cases [18]. In a Spanish study, these proportions resulted significantly lower (11% and 25%, respectively) [19]. This difference could be attributable to population heterogeneity or to a clinical selection or failure to detect mutations by the technology used (single-strand conformation polymorphism, SSCP, analysis).

A total of 144 distinct mutations in the BMPR2 gene have been so far described in 210 patients with pulmonary arterial hypertension [20]. Approximately 70% of the BMPR2 mutations underlying pulmonary artery hypertension are predicted to lead to premature truncation of the BMPR2 transcript and are likely to be lost by the process of nonsense-mediated decay. All the currently known mutations cause a loss of receptor function.

Recent studies suggest that BMPR2-related IPAH is due to the failure of BMPR2 opposing a competing TGF-β signalling function, whose activation causes an increase in the TGF-β activity that has been shown to promote fibrogenesis, intimal hyperplasia and smooth-muscle growth [21, 22]. This hypothesis implies that the fundamental mechanism of BMPR2-related pulmonary artery hypertension is an imbalance of growth signalling caused by a reduction in the braking function of BMPR2.

As the pathophysiology of IPH remains largely unknown and IPH and IPAH share similar histopathological vascular lesions, we hypothesized that mutations in the BMPR2 gene may be found in patients with IPH. Consequently, the aim of this study was to assess the prevalence of mutations in BMPR2 in patients with IPH.

**Materials and methods**

**Patients**

Diagnosis of IPH was based on the following criteria: (1) presence of unequivocal signs of portal hypertension (gastroesophageal varices, ascites, splenomegaly and/or presence of portosystemic collaterals), (2) absence of cirrhosis or advanced fibrosis or of other additional causes of chronic liver diseases causing portal hypertension, at liver biopsy (performed in all patients), (3) absence of hepatic or portal vein thrombosis at imaging studies performed at diagnosis, (4) absence of toxic exposure to arsenic, vinyl chloride or copper sulphate (clinical history). All liver biopsy specimens were re-evaluated for the purpose of the study by an experienced pathologist (M.B.). These criteria were selected based on two reference papers from Japan and Europe [23, 24].

Patients with IPH followed-up at the Liver Unit of our Hospital, who have given written informed consent to obtain a blood sample for genetic studies, were considered eligible for the study. To avoid genetic noise related to inherited genetic traits and to have a homogeneous ancestry population we selected only caucasian patients for the study. Because of the exploratory nature of this study and the elevated costs, the study was limited to the initial consecutive 23 patients.

The protocol was approved by the Institutional Review Board of Hospital Clinic in Barcelona. Clinical, epidemiological, laboratory and imaging features were recorded in a pre-designed case report form.

**BMPR2 gene molecular studies**

Aliquots of whole blood were stored at ~80°C. DNA extraction from whole blood was performed using an automatic MagNA Pure system (Roche Diagnostics, Madrid, Spain) according to the manufacturer instructions.

BMPR2 exons and their associated boundary regions were amplified by PCR with previously reported primers [15, 19]. PCR products were sequenced using the Big-Dye Terminator Chemistry Kit v3.1, run on an ABI3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and analysed using ABI PRISM GeneMapper software version 3.0. All sequences were compared to NCBI RefSeq NM_001204.6. The standard nomenclature recommended by HGVS (www.hgvs.org/mutnomen) was used to number nucleotides and name mutations.

Frequencies of BMPR2 SNPs were compared to those previously described in the HapMap database (http://hapmap.ncbi.nlm.nih.gov/index.html.en).

**Multiple ligation probe amplification (MLPA) reaction**

Multiple ligation probe amplification analysis was performed with Salsa P093-B2 HHT (MRC-Holland, Amsterdam, the Netherlands) as described previously by Madrigal et al. [25]. Samples were loaded onto an ABI3130 Genetic Analyzer and results were visualized using the Gene Mapper program and analysed with the SEQUENCE Pilot-module MLPA® program (JSI Medical Systems GmbH, Kippenheim, Germany).

**Quantitative polymerase chain reaction (qPCR)**

DNA copy number of two BMPR2 genes was determined by qPCR using SYBR Green on an ABI PRISM 7300 Real-Time PCR System (Applied Biosystems). Primers were designed for exons 4, 9, 11 and 12 (4F-CAGCCTTTTCTAAAGGGGAGTCTC, 4R-CCAAGCATAGGCACTATCTC, 9F-AGAATATGC-TACGTTTCTC, 9R-CCTGGGAAAGGTCGTAGACCT; 12F-CAGGCAGTGGTGACTCTA; 11R-TGATAGATGCCACACCTCTa; 12F-GTGTCGCAAAATTGGTCCTC, 12R-CTTGCTGTGGTGCCTCTCAT). Each reaction was performed in triplicate. Amounts of DNA in each amplification were determined by comparing the results to a standard curve produced by real-time PCR of serial dilutions (e.g. undiluted, 1:4, 1:16 and 1:64) of a known amount of DNA.

**RNA extraction and cDNA synthesis**

Total RNA was extracted from peripheral blood using the PAXGene Blood RNA Kit following their basic protocol (Qiagen, Germany). RNA
concentration and purity were measured with a spectrophotometer (NanoDrop™ Spectrophotometer ND-100; Thermo Fisher Scientific, Madrid, Spain). Finally, cDNA was synthesized with 200 ng of the extracted RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to manufacturer’s instructions.

**Real-time quantitative PCR (RT-qPCR) and data analysis**

Real-time quantitative PCR experiments were carried out in an ABI 7300 Real-Time PCR System (Applied Biosystems). No cDNA was added to negative control reactions. Beta-glucoronidase (GUS-H9252) was used as a housekeeping gene RT-qPCR and analysis was performed as previously described [26].

**mRNA expression analysis**

PCR was performed using cDNA to amplified exons 4, 11 and 12 of BMPR2 gene. Primers used were the ones previously described at the quantitative real-time PCR method.

**Results**

**Study population**

Clinical, demographic characteristics and laboratory findings of the 23 patients with IPH (21 unrelated) included in the study are shown in Table 1. Five patients belonged to three unrelated families (two brothers, a father and a son both included in the study and a woman whose sister was not included in the study). Three patients presented features associated with immunological diseases. The first one was diagnosed with rheumatoid arthritis, the second suffered from anti-phospholipid syndrome and the third one was a patient with positive anti-transglutaminase antibodies, but with a normal duodenal biopsy.

**Mutation analysis of the BMPR2 gene**

We did not detect any causative mutations in the BMPR2 gene in the 21 unrelated patients with IPH included in the study. However, in 12 patients SNPs were detected. Four patients presented one SNP in intron 5 (rs7575056), four patients had a SNP in exon 12 (rs1061157) and two patients had a SNP in exon 1 (5’-UTR-301G>A). Two additional patients had both polymorphisms at intron 5 and exon 12. No other SNPs were identified.

All SNPs that we found have been previously described in the HapMap database (http://hapmap.ncbi.nlm.nih.gov/index.html.en). The prevalence of these SNPs in our patients was similar to the prevalence described in the healthy caucasian population.

**Multiple ligation probe amplification**

Screening of BMPR2 by using the MLPA technique revealed five patients with possible duplications of BMPR2 gene: two patients presented a duplication of exon 4, one patient of exon 9 and two other patients of exons 11 and 12.

Quantitative PCR only confirmed three of these duplications in two patients (exon 4) and one patient (exons 11 and 12). However, these duplications do not alter the normal expression of the gene, regarding RNA studies.

| Table 1 | Clinical, demographic characteristics and laboratory findings of the 23 patients with IPH included in the study |
|---------|---------------------------------------------------------------|
|          | Median (range) or n (%)                                      |
| Number of patients | 23                                                          |
| Age at diagnosis of IPH | 28 (9–86)                                                   |
| Gender (male) (%) | 14 (61%)                                                    |
| HCV infection | 0 (0%)                                                      |
| HBV infection | 1 (4%)*                                                     |
| HIV infection | 4 (17%)                                                     |

**Signs of portal hypertension**

| Presence of oesophageal or gastric varices | 23 (100%) |
| Ascites | 5 (22%) |
| Splenomegaly | 17 (74%) |

**Laboratory data†**

| Leucocytes (G/L) | 4.7 (1.2–8.9) |
| Haemoglobin (g/L) | 128.8 (100–167) |
| Platelet count (G/L) | 112 (27–308) |
| Prothrombin time (%) | 75 (40–100) |
| Creatinin (mg/dl) | 0.87 (0.60–1.28) |
| AST (IU/l) | 39 (17–95) |
| ALT (IU/l) | 38 (12–95) |
| GGT (IU/l) | 81 (7–423) |
| Total bilirubin (mg/dl) | 1.45 (0.40–7.8) |
| Sodium (mEq/l) | 140 (135–145) |
| Albumin (g/l) | 42 (32–51) |

IPH: idiopathic portal hypertension. *HBV past infection. †Data at the time of blood draw for genetic analysis.
Discussion

Mutations in BMPR2 gene have been involved in the pathogenesis of IPAH [27]. Based on the observation that IPAH and IPH share common vascular alterations, our aim was to investigate whether IPH also present mutations in the BMPR2 gene.

In contrast to our initial hypothesis, in this study we did not find any possible causative mutations in the BMPR2 gene in patients with IPH. In addition to this finding, several other results that have emerged from this study, i.e. the confirmation of known SNPs and DNA duplications, as well as an unchanged mRNA expression, clearly argue against a possible role of BMPR2 in the pathogenesis of IPH. Structural alterations such as deletions or duplications affecting the BMPR2 gene have been described as a cause of familial pulmonary hypertension. In our samples, however, although at DNA level we have found some duplications, we could not confirm the alteration at mRNA and cDNA levels.

Previous studies in IPAH included small number of patients (less than 50) and the prevalence of BMPR2 mutations was up to 26% [28]. One of the largest series included 126 patients with IPAH and the prevalence was 21% [18]. Also an increased occurrence of BMPR2 duplications has been reported in IPAH [29].

With the lack of evidence of any BMPR2 mutation in this study and bearing in mind the low prevalence of IPH in western countries [5, 30], the number of patients in this study should be considered sufficient to reasonably believe that mutations in this gene may not be involved in the pathogenesis of IPH. Similarly, studies in familial PAH including a highly variable number of patients showed a prevalence of BMPR2 mutations of up to 82% [31]. Consequently, more than one of our patients should have had the BMPR2 mutation, reinforcing the finding that BMPR2 gene mutations are not involved in the pathogenesis of familial forms of IPH.

Our study, however, showed that in 12 patients (52%) with IPH three different SNPs were detectable. The three SNPs identified in our patients, in intron 5, exon 12 and exon 1, have been previously described in a normal population with the same prevalence as in the population of our study. In addition, the possibility that BMPR2 mutations occur in a subpopulation of patients with IPH also remains potentially open, because the sample size in this study (21 unrelated patients) was relatively small. However, due to the low prevalence of this disease in western countries [5, 30], the number of patients in this study should be considered sufficient to reasonably exclude this hypothesis.

It is currently recognized that up to 30% of hereditary and 80% of idiopathic cases of pulmonary artery hypertension do not have mutations identified in BMPR2 despite comprehensive testing. Hence, it is likely that mutations at one or more other loci contribute to the pathogenesis of IPAH, as demonstrated by the association of IPAH with hereditary haemorrhagic telangiectasia and mutations in activin-like kinase type 1 and endoglin [32]. Similarly, familial or IPH may be associated with mutations in genes other than BMPR2.

An association of IPH with immunological abnormalities has been described [8, 9]. In this study we identified three patients in whom an autoimmune disease was known. However, due to an important diagnostic heterogeneity, we recognize that it is not possible to draw any conclusions from this study in terms of relationship between autoimmunity and the development of IPH.

Idiopathic portal hypertension has also been associated with HIV infection [33] and recent data by Caldwell et al. [34] indicate that HIV may repress BMPR2 transcription in macrophages. In the present study we focused on possible genetic alterations in the BMPR2 gene and we did not assess the level of expression of BMPR2. Considering this methodological difference, whether the expression of BMPR2 was decreased in HIV patients in this study remains unknown. This intriguing hypothesis deserves further investigation.

In conclusion, the data of this study suggest that, in contrast to IPAH, IPH is highly unlikely that mutations in the BMPR2 gene were involved with pathogenesis of IPH. Idiopathic portal hypertension may be related to other mutations in the TGF-β superfamily and further investigation is needed to understand the pathogenesis of this condition.

Acknowledgements

This study was supported by grants from the Ministerio de Educación y Ciencia (SAF 10/17043) and Instituto de Salud Carlos III (PI 09/01261). Ciberehd is funded by Instituto de Salud Carlos III. A.D.G. was supported by a Swiss National Science Foundation grant (PASM33-117294) and by a EASL postgraduate fellowship. S.S. was supported by Rio Hortega-Instituto de Salud Carlos III. M.M. received financial support from AGAUR (2009GR254).

Contributors: Study concept and design: J.C.G.P. and A.D.G. Acquisition of data: A.D.G., S.S., M.M., M.I.A. and M.B. Analysis and interpretation of data: A.D.G., S.S., M.M., M.I.A., J.G.A., J.B. and J.C.G.P. Drafting of the manuscript: A.D.G. and S.S. Critical revision of the manuscript for important intellectual content and statistical analysis: A.D.G., S.S., J.G.A. and J.C.G. Obtained funding: J.B. and J.C.G.P. Study supervision: J.C.G.P.

Conflicts of interest

The authors confirm that there are no conflicts of interest.
References

1. Okudaira M, Ohbu M, Okuda K. Idiopathic portal hypertension and its pathology. Semin Liver Dis. 2002; 22: 59–72.
2. Ohbu M, Okudaira M, Watanabe K, et al. Histopathological study of intrahepatic aberrant vessels in cases of noncirrhotic portal hypertension. Hepatology. 1994; 20: 302–8.
3. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990; 11: 787–97.
4. Bayan K, Tuzun Y, Yilmaz S, et al. Analysis of inherited thrombophilic mutations and natural anticoagulant deficiency in patients with idiopathic portal hypertension. J Thromb Thrombolysis. 2009; 28: 57–62.
5. Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut. 2002; 51: 275–80.
6. Kono K, Ohnishi K, Omata M, et al. Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits. Gastroenterology. 1988; 94: 7632–6.
7. Huet PM, Guillaume E, Cote J, et al. Noncirrhotic presinusoidal portal hypertension associated with chronic arsenical intoxication. Gastroenterology. 1975; 68: 1270–71.
8. Saito K, Nakanuma Y, Takegoshi K, et al. Analysis of inherited thrombophilic mutations and natural anticoagulant deficiency in patients with idiopathic portal hypertension, and association of autoimmune diseases with idiopathic portal hypertension: a report of four families. J Am Coll Cardiol. 2009; 54: S32–42.
9. Sargi G, Pezzella A, Gagginelli S, et al. Familial aggregation in noncirrhotic portal fibrosis: a report of four families. J Gastroenterol. 1987; 82: 1130–3.
10. Pietra GG. Histopathology of primary pulmonary hypertension. Chest. 1994; 105: 25S-6S.
11. De BK, Pal A, Santra A, et al. Primary pulmonary hypertension in non-cirrhotic portal fibrosis. Indian J Gastroenterol. 1997; 16: 85–7.
12. Rosenzweig BL, Imamura T, Okadome T, et al. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci USA. 1995; 92: 7632–6.
13. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PHH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000; 67: 737–44.
14. Johnson JA, Vencak-Jones CL, Cogan JD, et al. Copy-number variation in BMPR2 is not associated with the pathogenesis of pulmonary arterial hypertension. BMC Med Genet. 2009; 10: 58.
15. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet. 2000; 26: 81–4.
16. Aldred MA, Vijayakrishnan J, James V, et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat. 2006; 27: 212–3.
17. Portillo K, Santos S, Madrigal I, et al. Study of the BMPR2 gene in patients with pulmonary arterial hypertension. Arch Bronconeumol. 2010; 46: 129–34.
18. Machado RD, Aldred MA, James V, et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat. 2006; 27: 121–32.
19. Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002; 105: 1672–8.
20. Akhurst RJ. TGF beta signalling in health and disease. Nat Genet. 2004; 36: 790–2.
21. Okuda K. Non-cirrhotic portal hypertension versus idiopathic portal hypertension. J Gastroenterol Hepatol. 2002; 17(Suppl. 3): S204–13.
22. Schouten JN, Garcia-Pagan JC, Valla DC, et al. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011; 54: 1071–81.
23. Madrigal I, Rodriguez-Revenge L, Badenas C, et al. MLPA as first screening method for the detection of microduplications and microdeletions in patients with X-linked mental retardation. Genet Med. 2007; 9: 117–22.
24. Avendano C, Franchi A, Jones E, et al. Pregnancy-specific (beta)-1-glycoprotein 1 and human leukocyte antigen-E mRNA in human sperm: differential expression in fertile and infertile men and evidence of a possible functional role during early development. Hum Reprod. 2009; 24: 270–7.
25. Newman JH, Phillips JA, 3rd, Loyd JE. Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies. Ann Intern Med. 2008; 148: 278–83.
26. Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germine mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet. 2000; 37: 741–5.
27. Cogan JD, Pauciulo MW, Batchman AP, et al. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006; 174: 590–8.
28. Dhiman RK, Chawla Y, Vasishta RK, et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol. 2002; 17: 6–16.
29. Machado RD, Eickelberg O, Elliott CG, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54: S32–42.
30. Szturm B, Yalcin A, Girend B, et al. Genes and pulmonary arterial hypertension. Respiration. 2007; 74: 123–32.
31. Chang PE, Miquel R, Blanco JL, et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol. 2009; 104: 1707–14.
32. Caldwell RL, Gadjipati R, Lane KB, et al. HIV-1 TAR represses transcription of the bone morphogen protein receptor-2 in U937 monocytic cells. J Leukoc Biol. 2006; 79: 192–201.